Amantin

Amantin Mechanism of Action

escitalopram

Manufacturer:

Akums Drug

Distributor:

Bell-Kenz Pharma

Marketer:

Ambica
Full Prescribing Info
Action
Pharmacotherapeutic group: Antidepressants, selective serotonin reuptake inhibitors.
Pharmacology: Pharmacodynamics: Mechanism of Action: Escitalopram is a selective inhibitor of serotonin (5-HT) re-uptake. The inhibition of 5-HT re-uptake is the only likely mechanism of action explaining the pharmacological and clinical effects of Escitalopram. Escitalopram has no or low affinity for a number of receptors including 5-HT1A, 5-HT2, DA D1 and D2 receptors, α1-, α2-, β-adrenoceptors, histamine H1, muscarine cholinergic, benzodiazepine and opioid receptors.
Pharmacokinetics: Absorption is independent of food intake (mean Tmax is 4 hours after multiple dosing). The apparent volume of distribution (Vd, beta/F) after oral administration is about 12 to 26 L/kg. The plasma protein binding of Escitalopram is approximately 55%.
Escitalopram is metabolised in the liver to the didemethylated metabolites and partly excreted as glucuronides. Unchanged Escitalopram is the predominant compound in plasma. After multiple dosing the mean concentrations of the dimethyl and didemethyl metabolites are usually 28-31% and 5% of the Escitalopram concentration, respectively. The elimination half-life after multiple dosing is about 30 hours and the oral plasma clearance is about 0.60 L/Min. Escitalopram and major metabolites are - like racemic citalopram - assumed to be eliminated by the hepatic (metabolic) and renal routes with the major part of the dose.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in